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ABSTRACT 
BACKGROUND 
The use of complementary and alternative medicine (CAM) is widespread in the treatment of 
menopausal symptoms. While observational studies indicate that CAMs can bring some relief 
of symptoms, there is mixed evidence of this based on clinical trials and other studies 
(Thompson, 2010 and Newton et al., 2006), with very little available research specific to South 
Africa. 
OBJECTIVES 
The primary aim of this study was to determine the use of complementary and alternative 
medicines in the treatment of menopausal symptoms by private health-care patients in 
Pretoria, South Africa, based on findings from a single site.   
Two secondary objectives were to gather information on the concurrent usage of CAMs and 
allopathic medicines, as well as to gather information on the sources of information utilised 
for CAMs. 
METHOD 
The study was cross-sectional and descriptive in design. The data was collected using a 
structured questionnaire to collect information from randomly selected participants at the 
study site, a private community pharmacy. The data collected included demographic details, 
participant’s attitude towards menopause, menopausal symptoms and treatments and 
sources that the participant utilised for information on CAMs.   
RESULTS 
The response rate for the study was 38.1%, based on an initial contact list of 197 potential 
participants.  The study found that 38.0% of all participants had used CAMs to treat their 
menopausal symptoms, with 48.1% of these using more than one CAM product.  CAM users 
reported significantly more severe menopausal symptoms than non-CAM users (p-value = 
0.02).  Around 63.0% of CAM users found at least one of the CAM treatments they used to be 
effective, with 43.1% of all individual CAM treatments being perceived as effective.  A small 
proportion of participants (18.3%) had used both CAM and HRT treatments concurrently.  
Nearly two thirds (63.0%) of CAM users consulted with their medical doctor in some way 
before initiating CAM treatment for their menopausal symptoms.  However, the single 
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primary source used by participants to gather information on CAMs was the internet, with 
59.3% of CAM users using the online resource as their primary information source.   
CONCLUSION 
The use of CAMs in the treatment of menopausal symptoms by private healthcare patients in 
Pretoria, South Africa is widespread, with 38.0% of participants in this study using them to 
treat their menopausal symptoms.  Future research should attempt to understand why CAM 
usage is associated with more severe menopausal symptoms.  Research comparing the 
prevalence of individual CAMs to their efficacy may also be illuminating. 
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1. Introduction 
1.1 Background 
Menopause is the permanent end of a woman’s menstrual periods, and is experienced by all 
women, typically between the ages of 40 and 58 years, with the average age being 51 years 
(The North American Menopause Society, 2017b).  In most cases menopause occurs naturally, 
but its onset may also be triggered by medical interventions such as pelvic radiation or 
chemotherapy causing damage to the ovaries, or by surgery such as a bilateral oophorectomy, 
which is the removal of both ovaries (The North American Menopause Society, 2017b).   
Many women experience symptoms with the onset of menopause, including urogenital, 
somato-vegetative and psychological symptoms (Berlin Centre for Epidemiology and Health 
Research, 2008).  These symptoms may affect a woman physically or psychologically, thereby 
altering her behaviour or impacting day to day activities, which may lead to an altered or 
decreased overall quality of life (QOL) (Moustafa et al., 2015).  The National Health Service 
(NHS) in the United Kingdom (UK) reports that women typically continue to experience these 
symptoms after the permanent end of their menstrual periods, with most symptoms lasting 
on average around four years from the last period (NHS Choices, 2015).  Around one in ten 
women continue to experience symptoms associated with menopause for up to twelve years 
(NHS Choices, 2015), and hot flushes can continue for up to fourteen years after menopause 
(Avis et al., 2015). 
Menopausal symptoms are a result of fluctuating and lowered oestrogen levels (Women’s 
Health Concern, 2015).  Hormone Replacement Therapy (HRT) has been widely used for 
decades as the standard conventional treatment for menopausal symptoms, typically in the 
form of either oestrogen alone, or oestrogen combined with progestin.  The 1920’s saw the 
first development of synthetic oestrogen, and by the mid 1930’s, HRT was being used to treat 
menopausal symptoms (Brett and Chong, 2001).  While the therapy is effective in the 
treatment of symptoms, trials have however shown serious risks with even short-term use 
(Newton et al., 2006). 
1.2 Problem statement 
The use of complementary and alternative medicines (CAMs) is globally widespread and is 
used to treat a broad range of conditions, including menopausal symptoms.  Worldwide, 
many women look to CAMs as an alternative to HRT (Women’s Health Concern ,2015).  This 
can be in direct response to adverse side-effects of HRT such as bloating, headaches, water 
retention or nausea.  Others may have a belief that the manipulation of their hormones using 
synthetic oestrogen is unnatural, or principally wrong.  For many, the risks associated with 
http://etd.uwc.ac.za/
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HRT, such as increased risk of stroke, blood clots, heart attack and breast cancer, has 
encouraged the use of CAM treatments (Hill-Sakurai et al., 2008). 
A 2015 Women’s Health survey, conducted in the UK, (Women’s Health Concern, 2015) 
revealed that 95% of these women would try alternative therapies before HRT due either to 
concerns around the health risks of HRT, or to a preference for a more natural treatment.  
Further evidence from many studies suggest the worldwide prevalence of CAMs for the 
treatment of menopausal symptoms is high, although these were mostly observational 
studies (Posadzki et al., 2013) 
Many women in South Africa also look to CAMs as an alternative to HRT (South African 
Menopause Society, 2017).  Despite some CAM-allopathic drug interactions being dangerous 
and potentially fatal, many South African women believe that alternative and natural 
remedies are safer than allopathic alternatives, and in fact may not be aware of the risks 
associated with these interactions at all (Van der Westhuizen, 2009).  There is a need for 
pharmacists and other South African healthcare practitioners to inform women of possible 
CAM interactions with other drugs, as well as the potential side-effects of the CAM treatments 
themselves.  Black Cohosh is one such alternative treatment that has the potential to cause 
side-effects, including jaundice and gastric upset, although no studies have focused on 
sustained usage for more than 6 months (National Center for Complementary and Integrative 
Health, 2017). 
1.3 Motivation for study 
Many botanical therapies have been used as biologically-based treatments for menopause-
related conditions (Sonnedecker, 2006).  These foods and supplements are derived from 
plants and include a range of natural product classes (e.g. phyto-oestrogens such as the 
isoflavones found in soy or Red Clover) and individual natural products (e.g. Black Cohosh, St 
John’s wort, or Ginseng).  Despite their popularity, common herbal interventions such as Black 
Cohosh, soy and multibotanicals have been shown to have no clinically meaningful effects in 
the treatment of vasomotor symptom frequency or intensity, based on the results from 
several large, randomised, double-blind trials (Newton et al., 2006). 
Homeopathy as a complementary treatment has been delivered within the NHS in the UK 
since 1948 (Thompson, 2010).  Data on many observational studies (Clover, 2000; Richardson, 
2001; Spence et al., 2005) around homeopathic care as a treatment for the symptoms of 
menopause was collected from hospitals around the UK, with patients being assessed on the 
frequency and severity of symptoms.  Results indicated symptomatic benefits were perceived 
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by a number of patients; however, two randomised controlled trials (Thompson, 2010) did 
not indicate effectiveness of the treatments at a statistically significant level. 
Studies show that women tend to use more CAM products than men, and that within the 
female population, women experiencing menopausal symptoms are of the highest users of 
CAM products and therapies (Committee on the Use of Complementary and Alternative 
Medicine by the American Public, 2005).  While the use of CAMs is widespread in the 
treatment of menopausal symptoms, there is a shortage of scientific research in this area 
(National Centre for Complementary and Alternative Medicine, 2012).  Observational studies 
indicate that CAMs can bring some relief of menopausal symptoms, but these studies tend to 
be inconsistent in form, and there is mixed evidence of prevalence, efficacy or safety based 
on clinical trials and other studies (Thompson, 2010; Newton et al., 2006). 
Published research on CAM usage has been extremely limited in South Africa, although 
community pharmacies in South Africa do sell a range of CAM products.  Some of these 
products are indicated for the treatment of symptoms associated with menopause (MIMS, 
2016).  This study intends to measure the prevalence of the usage of these products to treat 
menopausal symptoms in the single pharmacy selected as the study setting, and to analyse 
the demographic attributes of CAM users.  
1.4 Research question 
How widespread is the use of complementary and alternative medicines in the treatment of 
menopausal symptoms by private healthcare patients in Pretoria, South Africa? 
1.5 Primary aims and objectives 
The primary aim of this study was to describe the use of CAMs in the treatment of menopausal 
symptoms by women who access private healthcare in Pretoria, South Africa.  
Two secondary objectives were to gather information on the concurrent usage of CAMs and 
allopathic medicines, as well as to gather information on the sources of information utilised 
for CAMs. 
http://etd.uwc.ac.za/
13 | P a g e  
 
2. Literature review 
2.1 Introduction 
The literature review begins with a review of treatments included in the CAM definition, 
followed by a review of the motivation for the usage of CAMs for menopausal symptoms and 
the concurrent usage of CAMs and allopathic medicines.  The final sections discuss six surveys 
on the use of CAMs for the treatment of menopausal symptoms. 
2.2 Scope of complementary and alternative medicines 
The United States National Centre for Complementary and Integrative Health (NCCIH) defines 
CAMs as a group of diverse medical and health care systems, practices and products that are 
not generally considered part of conventional medicine (U.S. National Library of Medicine: 
National Institutes of Health, 2003).  The NCCIH classifies CAMs therapies into 5 categories 
(U.S. National Library of Medicine: National Institutes of Health, 2003): 
1. Alternative medical systems, 
2. Mind-body interventions, 
3. Biologically-based systems e.g. botanicals, herbalism, vitamins, minerals, amino acids 
4. Manipulative and body-based methods e.g. massage, chiropractic, and, 
5. Energy therapies. 
While this study focused primarily on biologically-based systems (i.e. the third category 
classified by the NCCIH), a broader spectrum of treatments for menopausal symptoms could 
be considered complementary or alternative.  These include traditional healers and faith 
healers, as well as acupuncture, aromatherapy, meditation, neural therapy, static magnets 
and yoga, among others (Posadzki et al., 2013).   
In South Africa, the Medicines and Related Substances Act 101 of 1965 defines 
Complementary Medicine (Medicines Control Council, 2016) as:  
any substance or mixture of substances that—  
(a) originates from plants, fungi, algae, seaweeds, lichens, minerals, animals or other 
substance as determined by Council, and  
(b) is used or purporting to be suitable for use or manufactured or sold for use—  
(i) in maintaining, complementing, or assisting the innate healing power or physical or 
mental state, or  
(ii) to diagnose, treat, mitigate, modify, alleviate or prevent disease or illness or the 
symptoms or signs thereof or abnormal physical or mental state, of a human being or 
animal, and  
http://etd.uwc.ac.za/
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(c) is used—  
(i) as a health supplement, or  
(ii) in accordance with those disciplines as determined by Council, or  
(d) is declared by the Minister, on recommendation by the Council, by notice in the Gazette to 
be a complementary medicine. 
2.3 Motivation for usage of complementary treatments for menopausal symptoms 
Many women choose complementary and alternative treatments for their menopausal 
symptoms as a reflection of their personal beliefs and values (Sonnendecker, 2006).  Others 
are dissatisfied with the efficacy of allopathic hormonal medicines, or are concerned with the 
high risk or adverse effects of conventional treatments, primarily HRT (Sonnendecker, 2006). 
While there is no single common reason for women to use CAMs for the treatment of their 
menopausal symptoms, there are four broad themes that emerge when describing women’s 
decisions in this regard (Hill-Sakurai et al., 2008).  The first is that the approach is “natural”, 
often referring to a perception that treatments are safer or gentler, or that the approach does 
not involve physicians.  The second is that menopause is a life stage condition, rather than a 
medical one, and should therefore drive an individual prioritisation of personal health and 
wellness.  The third is that information about menopause is generated from personal 
experiences of friends and family, even though such experiential information may be 
disregarded by medical experts.  Finally, current usage of CAMs may drive patterned 
responses in individuals and direct future treatment choices (Hill-Sakurai et al., 2008). 
There are a wide range of symptoms associated with menopause.  Common menopausal 
symptoms include hot flushes, sleep problems, night-time sweating, heart palpitations, 
muscle and bone pain, vaginal dryness, depressive moods, and a lack of energy.  Women may 
experience various combinations of these symptoms, with varying perceived severities.  The 
Menopause Rating Scale (MRS II) (Berlin Centre for Epidemiology and Health Research, 2008), 
is one measurement tool that has been designed to represent the severity of menopausal 
symptoms.  It asks women to rate the severity of their own menopausal symptoms in 11 
individual categories, with each category rated on a five-point scale, ranging from “None” to 
“Very Severe”.   
A number of CAM products and treatments are associated with the relief of menopausal 
symptoms.  For example, phyto-oestrogens, black cohosh and magnesium bring benefits 
associated with hot flushes (Sonnedecker, 2006; Tonick and Muneyyirci, 2016), omega 3 
brings benefits associated with lubrication of body tissues thus assisting with vaginal dryness 
(Menopause Centre Australia, 2016), while omega 6 brings benefits associated with night 
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flushes (Sonnedecker, 2006).  Calcium can prevent bone loss (University of Maryland Medical 
Center, 2105a) and magnesium can improve insomnia, irritability, agitation and anxiety 
(University of Maryland, 2015d).  However, usage of CAMs may also be associated with 
symptomatic risks including gastro-intestinal disturbances for black cohosh, omega 3 and 
calcium (Sonnedecker, 2006), endometrial hyperplasia from soy products (Sonnedecker, 
2006) and nausea or vomiting from both omega 6 and magnesium (Sonnedecker, 2006; 
University of Maryland Medical Center, 2015d).   
Many women use CAMs in conjunction with allopathic medicines (Peng et al., 2014; Van der 
Sluijs et al., 2007).  A concern is that the tendency to use herbal products and allopathic 
medicines concurrently can result in herb-drug interactions (Fasinu et al., 2012).  The 
pharmacologic properties of herbal products have been observed to induce 
pharmacodynamic interactions, potentially including synergistic, additive or antagonistic 
effects.  Various pharmacokinetic interactions have also been identified, such as the 
alteration of gastrointestinal functions, inhibition of metabolic enzymes and alteration of 
renal excretion of drugs (Fasinu et al., 2012).  These potential interactions highlight the 
benefit of studies on the concurrent usage of CAMs and allopathic medicines. 
2.4 Review of global surveys  
Several studies on the use of CAM treatments to treat menopausal symptoms have been 
conducted globally and the results of these reference studies are summarised in Table 1.  The 
objectives of these studies were generally to describe the prevalence rates of CAM usage for 
menopausal symptoms within the target demographic, as well as to document the perceived 
effectiveness of these treatments.  Most of these studies were performed predominantly in 
developed countries and recorded prevalence of CAM use ranging from 23 to 83%     
In addition, several secondary factors have been included in some of these studies.  These 
include the concurrent usage of CAMs with allopathic medicines, interaction and 
communication with medical practitioners regarding information and recommendations on 
CAMs, and prevalence of non-medicine based treatments. 
While all the studies used a cross-sectional questionnaire to collect data, it is worthwhile to 
note that the studies did not all use the same questionnaire.  Furthermore, five of the six 
studies used a standardised scale of some sort to measure the severity of menopausal 
symptoms.  The study conducted in Germany by Buhling et al. (2014) used the MRS II, and 
both Cardini et al. (2010) and van der Sluijs et al. (2007), used a symptom rating scale very 
similar to MRS II but not identical.  Both these studies used the same rating scale to measure 
the severity of menopausal symptoms, with a severity rating of 0 to 6 collected across 15 
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symptoms.  Gerber et al. (2014) used similar symptom groupings as the MRS II (somatic, 
psychological and vasomotor instead of urogential) but applied a binary scoring method 
rather than a scale.  Gollschewki et al. (2004) also grouped symptoms into three categories 
(physical, psychological and vasomotor) with a severity rating scale of 0 to 3, however they 
included 21 symptoms (Greene, 1976). 
While the various surveys had broadly similar objectives, the data collected as well as the 
inclusions and exclusions for each study were not standardised and thus are challenging to 
compare and aggregate directly.  However, the various studies tend to utilise a common set 
of references and cross-citations. 
2.5 South African context 
The South African regulatory definition of complementary medicine mentioned in section 2.1 
(Medicines Control Council, 2016) covers four broad disciplines of complementary 
treatments: 
• Western Herbal preparations, 
• Traditional Chinese, Ayurvedic and Unani Tibb substances, 
• Homeopathic preparations, and, 
• Aromatherapy substances. 
A notable exclusion from this list is African Traditional Medicines (ATMs), which were not 
included as one of the CAM disciplines in the South African definition of complementary 
medicine, because of its complex and political disposition in post-apartheid South Africa.  
However, the use of traditional healers in South Africa has seen a general decline over the 13 
years leading up to 2009, based on several published and unpublished research studies 
(Peltzer, 2009).  In addition, ATMs are not routinely sold in community pharmacies in South 
Africa and are thus beyond the scope of this study.  The exact range of complementary 
treatments that are offered by a particular community pharmacy in South Africa would 
depend largely on the demographic and socio-economic profile of the community which they 
serve.  In their 2014 guideline on the quality, safety and efficacy of complementary medicines, 
the Medicines Control Council states that “In general Complementary Medicines (CMs) are 
used and sold by many people in RSA.” (Medicines Control Council, 2014), indicating broad 
usage patterns in South Africa. 
Both public and private healthcare services are available in South Africa.  The public sector is 
state-funded with aggregate healthcare expenditure accounting for 11% of the government’s 
total budget (Jobson, 2015).  Consumers that elect to access private healthcare services such 
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as community pharmacies tend to correspond to a comparatively higher Living Standards 
Measure (LSM) (Hospital Association of South Africa, 2008) than consumers that use only 
public healthcare services.  While public facilities do offer some CAMs treatments, private 
facilities would offer a far broader range of CAMs options. 
In general, CAMs are used by a substantial proportion of the general population, for a broad 
range of conditions and symptoms.  In a 2008 study, only a third of South African women 
believed that soy could be used as an alternative to HRT, and less than a quarter reported 
that its usage would relieve menopausal symptoms, despite over 60% acknowledging its 
benefit for preventing cardiovascular disease and osteoporosis (Bosman et al., 2008). Yet, 
several CAMs may have potentially fatal interactions with allopathic drugs and treatments 
(Van der Westhuizen, 2009).  For instance, the Western herbal preparation St John’s Wort 
(Hypericum perforatum) can be used by women to treat depressive moods associated with 
menopausal symptoms.  Patients that use this concurrently with tricyclic antidepressants, 
selective serotonin reuptake inhibitors and monoamine oxidase inhibitor classes of anti-
depressants have been observed to develop serotonin syndrome, which can be fatal if left 
untreated (University of Maryland Medical Centre, 2007).  As such, South African pharmacists 
have an important role to play in informing women of possible side-effects and drug 
interactions (Van der Westhuizen, 2009) for women who use CAMs for menopausal 
symptoms. 
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Table 1: Studies showing the prevalence of CAMs use and most common CAM products and approaches to treat menopausal symptoms 
No Author’s 
name/ 
reference 
Study Design Target 
population 
and 
recruitment 
Geography Age 
Range  
Sample Size  Rating metric used 
to assess 
menopausal 
symptoms 
Prevalence of 
CAMs usage 
Most Common 
CAMs 
Treatment 
Used 
1 Buhling et al., 
2014 
Cross-
sectional 
study 
Postal 
questionnaire 
Insurance 
Broker Client 
List 
Germany 45-60 1893 MRS II 
(12 symptoms across 3 
categories, severity 
scale 0 to 4) 
48% Lifestyle 
Alteration 
(29%) 
St John’s Wort 
(18%) 
2 Van der Sluijs 
et al., 2007 
Cross-
sectional 
study 
Self-
administered 
questionnaire 
 
Menopause 
Clinics, GP 
Clinics and 
Government 
Health 
Agencies 
Sydney  
(Australia) 
45-65 1296 Similar to MRS II 
(15 symptoms, no 
grouping, severity scale 
0 to 6) 
 
54% Soy (25%) 
3 Cardini et al., 
2010 
Cross-
sectional 
study 
Self-
administered 
questionnaire 
Family 
Planning & 
Women’s 
Health Clinic, 
and 
Menopause 
Centre 
Bologna  
(Italy) 
45-65 1106 Similar to MRS II 
(15 symptoms, no 
grouping, severity scale 
0 to 6) 
 
34% Herbal (41%) 
http://etd.uwc.ac.za/
19 | P a g e  
 
4 Gerber et al., 
2014 
Cross-
sectional 
study 
Interview-
guided 
questionnaire 
Primary Care 
Centres (9) 
Qatar 40-60 814 Used an adapted 
SWAN assessment 
(3 symptom groupings 
similar to MRS II, binary 
severity rating) 
38% Nutritional and 
Herbal 
5 Gollschewki 
et al., 2004 
Cross-
sectional 
study 
Postal 
questionnaire 
Electoral Roll Queensland 
(Australia) 
47-67 885 Greene Climacteric 
Scale  
(21 symptoms across 3 
categories, severity 
scale 0 to 3) 
83% Nutrition (76%) 
Phyto-
oestrogens 
(56%) 
6 Bosman et 
al., 2008 
Cross-
sectional 
study 
Face-to-face 
interview 
1996 Census 
Data across 
all 9 
provinces 
South 
Africa 
50-59 825 n/a 
(no section on severity 
of symptoms) 
n/a 
(study was on 
attitudes/beliefs 
not usage) 
Soy 
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3. Methodology  
3.1 Study design 
The study was cross-sectional and descriptive in design.  A structured questionnaire (Appendix 1) was used 
to collect the information from the randomly selected participants.  This design was selected to provide the 
best comparability to related global and South African studies while still providing the level of detail 
necessary to effectively meet the study aims and objectives. 
3.2 Study setting 
The study was a single-site study conducted at a private community pharmacy with a clinic in Pretoria, South 
Africa.  
3.3 Recruitment of participants 
The target demographic for the study was women aged 40-65 years that had experienced symptoms 
associated with menopause.  Women with co-existing medical conditions such as diabetes, hypertension, 
arthritis etc. were eligible for inclusion in this study.  Women whose menopause was triggered by damage 
to the ovaries from radiation, chemotherapy or other drugs or a bilateral oophorectomy were excluded from 
the study. 
The sampling for the study was done using the customer database at the pharmacy and this was the primary 
source for the recruitment of participants.  The sampling strategy used a representative sample based on 
the pharmacy family birthday list.  From this list, the following exclusions were applied: 
• Men, 
• Women whose age was not between 40 and 65 years, 
• Physical address not in Pretoria, 
• Inactive customers, and, 
• No telephonic contact details. 
This exclusion process yielded 214 potential participants who were shortlisted as eligible for inclusion and 
each was assigned a unique anonymous participant number by the researcher.  The researcher, in her 
capacity as pharmacist at the study setting, used the database contact details to attempt to contact all 
shortlisted individuals telephonically to inform them of the study and invite them to participate.  An 
additional two attempts were made to contact potential participants that were not immediately reachable. 
Contacted individuals that agreed to participate in the study were invited to receive and read the Study Pack, 
which included the Study Information Sheet (Appendix 2), Informed Consent (Appendix 3), and 
Questionnaire (Appendix 1), which could be collected in printed form at the pharmacy, or sent via email.   
Those that opted out of the study were not contacted again. 
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3.4 Data collection and analysis 
To validate the questionnaire, two women known to the researcher were invited to complete the 
questionnaire in a pilot study.  The researcher requested feedback regarding the time taken to complete the 
questionnaire as well as ease and comprehension of the questions.  The final questionnaire was revised as 
per the feedback received. 
A structured questionnaire was used to collect the data from the participants.  The participants were given 
the option to complete the questionnaire unassisted or with the assistance of the researcher (interview 
guided).  Those participants who selected the self-administered route were invited to contact the researcher, 
either at the study setting, telephonically or by email should they need clarity on any of the questions in the 
questionnaire. 
The questionnaire was designed to capture all information required to meet the primary and secondary 
objectives of the study, with specific focus on those variables required to identify and describe CAM usage 
for the treatment of menopausal symptoms.  The questionnaire consisted of 17 questions, divided into four 
sections: 
• Section 1 (questions 1 to 5) related to the demographic details of the participant, including age, race, 
marital status, education level and employment status.  
• Section 2 (questions 6 and 7) dealt with the participant’s attitude toward menopause. 
• Section 3 (questions 8 to 12) focused on menopausal symptoms and treatment. 
• Section 4 (questions 13 to 17) focused on the sources that the participant utilised for information on 
CAMs.  This section was only completed by participants who indicated CAM usage for menopausal 
symptoms in Question 12. 
Other than questions 11 and 12, the questionnaire consisted of simple categorical questions that could be 
rapidly answered, mostly in the “select one option” or “select all options that apply” pattern.  This approach 
allowed the questionnaire to be rapidly completed by the respondent and minimised the risk that questions 
would be misunderstood or omitted. 
Question 11 asked the participant to rate their own menopausal symptoms across 11 specifically defined 
symptoms, as defined in MRS II.  For each symptom, the participant had to select a severity on the scale 
ranging from none, mild, moderate, severe and very severe.  Section 3.5 describes the MRS II scale in detail, 
including its development and validation. 
Question 12 asked the participant to detail their usage of all allopathic medicines, CAM, and supplements.  
For each product, the participant had to define its effectiveness on a three-point scale: effective, partially 
effective or ineffective. 
Completed questionnaires were collected by the researcher as either a print-out at the study setting, or as 
a scanned attachment to an e-mail from the participant.  Those questionnaires that were received 
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electronically were printed out by the researcher.  Each questionnaire was physically labelled with the 
unique participant number pre-allocated to that participant at the time of their entry into the study and used 
on the signed informed consent form. 
The data from each questionnaire was captured by the researcher into the anonymous coding sheet, 
mastered in Microsoft® Excel®, and later verified to minimise capturing errors.  This was used to create a 
single data table view with each participant representing a row in the data table, and each question or sub-
question representing a column.  For categorical data, standard coding was used across each participant to 
ensure that the data could be analysed easily. 
The data table was analysed using a range of statistical methods in Microsoft® Excel®.  These include 
descriptive techniques to describe the demographic breakdown of the participants, the prevalence of CAM 
usage per demographic attribute and overall sample, and analysis of variance to analyse the differences 
between group means.  These statistics allowed some inferences to be drawn from the sample population. 
The responses from Question 12 (medications used and their perceived efficacy) were recorded in a separate 
data table and were captured verbatim from the questionnaire.  These responses were analysed individually 
by the researcher, who used her professional training to identify and categorise CAM treatments for 
menopausal symptoms, and to analyse usage of allopathic medicines, in line with the research objectives 
and prevailing literature.  CAMs users in the context of the study findings included only participants who 
treated their menopausal symptoms with biologically-based systems as categorised in the NCCIH 
classification of CAMs therapies.  These include botanicals, herbalism, vitamins, minerals and amino acids 
(U.S. National Library of Medicine: National Institutes of Health, 2003).  The study findings and statistical 
analyses are presented in chapters 4 and 5. 
3.5 Menopause rating scale 
One variable that the study aimed to investigate as a driver for the usage of CAMs was the severity of 
menopausal symptoms.  To test this correlation effectively, it was necessary to formulate an objective 
measurement for the severity of menopausal symptoms, or at least a validated ranking within the sample.  
One such measurement that is supported by the literature is the MRS II, and this measurement was applied 
in the questionnaire and analysis. 
The MRS II is a QOL scale developed in the early 1990’s, and further refined to its final MRS II version in 1996.  
The scale was built and calibrated based on the evaluation of a questionnaire that was sent out to 689 
German women aged between 40 to 60 years (Berlin Centre for Epidemiology and Health Research, 2008). 
MRS II is a questionnaire-based approach that analyses menopausal symptoms in 11 categories across 3 
dimensions (somato-vegetative, psychological and urogenital), with severity measured on a 5-point Likert 
scale, from “none” (0 points) to “very severe” (4 points).  The somato-vegetative dimension includes 
symptoms such as hot flushes, heart or muscular discomfort and sleeping problems.  The psychological 
dimension covers depressive moods, irritability, anxiety and exhaustion.  The urogenital dimension includes 
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sexual or bladder problems, as well as vaginal dryness.  The score for each dimension is calculated by adding 
up the category scores in the respective dimension.  These dimensions are ultimately combined to form an 
overall MRS score, ranging from 0 to 44, which is a validated measure for severity of menopausal symptoms. 
Development of MRS II has validated that the questionnaire can be self-administered should the participant 
wish to do so, and can be completed within 10 minutes.  Individual questions have a low omission rate since 
women do not typically feel the questions to be too private or sensitive (Heinemann, 2007). 
Validation of the scale was confirmed through an open post-marketing study of 3282 women (Dinger et al., 
2006), which confirmed evidence for the scale to measure treatment effects on QOL.  The MRS scale can be 
applied in women irrespective of age, and its application is not limited by ethnicity, social class, health status 
or geographic region. 
3.6 Ethical considerations 
Permission to conduct this study was granted from the University of the Western Cape’s Biomedical Science 
Research Ethics Committee on 18 August 2017 (ref BM17/6/20) using the prescribed form and process.  
Permission was also granted from the community pharmacy to conduct the research at their premises, use 
their customer database to select participants, and contact their customers directly to request their 
participation in the study.  Permission was granted by the owner of the pharmacy on 12 May 2017. 
Participants’ ethical rights and the ethical standards that this study conforms to were adhered to during the 
data collection process. No personal identifying information of participants was included in the 
questionnaire or published in this final research report. 
Potential participants were selected from the pharmacy’s customer database.  Once identified, each 
potential participant was contacted to inform them of the study and to request their participation.  If the 
potential participant showed an interest in participating in the study a study information sheet explaining 
the details of the study was handed to them in person at the pharmacy at an arranged time, or via email if 
so requested.  The informed consent, and the importance of understanding and signing it before 
participating in the study was explained to each participant.  Each willing participant signed the informed 
consent before any data was obtained from them. 
Each participant in the study was assigned a unique participant number that formed part of the coding of 
the study.  The decoding document which maps any individual completed questionnaire to the personal 
identification of that participant was only available to the researcher.  The informed consent and 
questionnaires were kept separately to ensure participant anonymity. 
The electronic data extraction sheet and any data analysis contained only the unique participant numbers 
of each participant in the study and could not be mapped back to any personal participant details.  Once the 
research is completed and all reports, publications, or other output have been complied, the electronic 
databases as well as all other data collection tools will be deleted and destroyed. 
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This study raises no concern about patient safety or medical welfare.  The researcher in this study was 
employed as a pharmacist at the study setting, and as a result, the researcher was also acting as the 
participant’s health care professional.  There was a possibility that the researcher might become aware of 
new health problems or concerns that came to light during the interview process or data coding process.  In 
such a case, the researcher committed to advise and/or refer the participant to the relevant health care 
professional for further care and treatment.  There was no anticipated direct benefit to the participants 
because of their participation in the study. 
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4. Findings  
4.1 Responses 
The database selection process yielded 214 potential participants for the study.  Seventeen of these 
individuals did not have current contact details on the customer database and could not be contacted, 
resulting in an initial contact list of 197 potential participants.  No response was received from 56 of these 
individuals despite several telephonic attempts made to reach them. 
The researcher successfully contacted 141 potential participants and determined that 35 of them were not 
eligible for inclusion in the study, mostly because they had not yet experienced menopausal symptoms and 
still experienced regular periods.  A further 12 individuals opted out of the study, indicating that they were 
either unable or unwilling to participate.  Ninety-four participants agreed to partake in the study following 
this initial contact period.  The initial contact and response process is illustrated in Figure 1 below. 
Figure 1: Questionnaire distribution and responses 
 
After being informed of the Study Pack, all the final 94 participants elected self-administration of the 
questionnaire rather than an interview-guided process.  Of the 94 participants that opted to participate in 
the study, a total of 75 completed questionnaires were ultimately submitted by participants, representing a 
response rate of 38.1% based on the initial contact list, and 53.7% when accounting for participants that 
opted out or were ineligible for inclusion.  Four participants had to be excluded from the 75 completed 
questionnaires because the onset of their menopausal symptoms was due to radiation, chemotherapy or 
other drugs or a bilateral oophorectomy.  The final sample size was therefore 71 participants. 
Database Selection (n=214) No Contact Details (n=17) 
Initial Contact List (n=197) No Response to Communication (n=56) 
Successful Contact Made (n=141) Ineligible (no menopause) (n=35) 
Opted Out (n=12) 
Opted In (n=94) No Questionnaire Returned (n=19) 
Questionnaires Returned (n=75) Questionnaire Exclusions (n=4) 
Final Sample (n=71) 
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4.2 Demographics of participants 
The demographic analysis of participants is provided in Table 2 below.  Analysis is presented for the entire 
sample (n=71) and split by participants who have used CAMs for the treatment of their menopausal 
symptoms (n=27) and those that have not (n=44).   
Table 2: Demographic analysis of participants (n=71) 
 Sample (n=71) CAMs Users (n=27) No CAMs (n=44) 
 Count Proportion Count Proportion Count Proportion 
AGE 
40-44 1 1.4% 
  
1 100.0% 
45-49 10 14.1% 4 40.0% 6 60.0% 
50-54 32 45.1% 13 40.6% 19 59.4% 
55-59 18 25.4% 6 33.3% 12 66.7% 
60-64 10 14.1% 4 40.0% 6 60.0% 
 71 100.0% 27 38.0% 44 62.0% 
       
RACE 
Asian 1 1.4% 1 100.0%     
Black 3 4.2% 1 33.3% 2 66.7% 
White 66 93.0% 25 37.9% 41 62.1% 
Omitted 1 1.4%    1 100.0% 
 71 100.0% 27 38.0% 44 62.0% 
       
MARITAL STATUS 
Divorced 8 11.3% 6 75.0% 2 25.0% 
Married 57 80.3% 21 36.8% 36 63.2% 
Single 4 5.6%     4 100.0% 
Widowed 2 2.8%   2 100.0% 
 71 100.0% 27 38.0% 44 62.0% 
       
HIGHEST LEVEL OF EDUCATION 
Matric 9 12.7% 3 33.3% 6 66.7% 
Diploma 18 25.4% 10 55.6% 8 44.4% 
Degree 16 22.5% 7 43.8% 9 56.3% 
Post-Graduate 28 39.4% 7 25.0% 21 75.0% 
 71 100.0% 27 38.0% 44 62.0% 
       
EMPLOYMENT STATUS 
Full-Time 31 43.7% 10 32.3% 21 67.7% 
Part-Time 5 7.0% 2 40.0% 3 60.0% 
Retired 7 9.9% 2 28.6% 5 71.4% 
Self-Employed 19 26.8% 8 42.1% 11 57.9% 
Unemployed 9 12.7% 5 55.6% 4 44.4% 
 71 100.0% 27 38.0% 44 62.0% 
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In comparison to the study target age range of 40 to 65 years, participants’ ages ranged from 44 to 64 years 
with a median age of 53 years.  Nearly a quarter of participants were aged 53 or 54.  The majority of 
participants in this study were white (93.0%, n=66).  Most (80.3%, n=57) of the participants were married, 
with a relatively small proportion of divorced (11.3%, n=8), single (5.6%, n=4) and widowed (2.8%, n=2) 
participants.  These overall proportions for race and marital status aligned with the reported demographics 
for CAM users across race (92.6% white) and marital status (77.8% married). 
In terms of highest level of education, participants with post graduate qualifications formed 39.4% of the 
total sample, however only 25.9% of CAM users reported having a post graduate qualification, compared to 
47.7% of participants that did not report CAM usage.  This may indicate that women with higher levels of 
formal education are less likely to use CAMs for the treatment of their menopausal symptoms.  However, 
using a 5% level of significance, a chi-square test provided no significant indication that there was a 
dependency relationship between CAM usage and educational level (p-value = 0.20).  
The second observation was that the proportion of CAM users that were unemployed (18.5%) appeared 
more than the sample proportion (12.7%), whereas the proportion of CAM users that were retired (7.4%) 
appeared lower than the sample proportion (9.9%), which may indicate a correlation between employment 
status and CAM usage.  However, using a 5% level of significance, a chi-square test provided no significant 
indication that there was a dependency relationship between CAM usage and employment status (p-value 
= 0.73).  It was not appropriate to test variable independence for marital status and race due to the large 
number of low expected frequencies in each case.      
As an extension to their basic demographic attributes, participants were asked to select the phrase that best 
described both their personal understanding of menopause, as well as their personal attitude toward 
menopause.  The responses are summarised in Table 3. Most participants viewed menopause as a natural 
life stage for women (85.9%, n=61), with only 12.7% (n=9) viewing it as a permanent chronic medical 
condition.  Furthermore, 47.9% (n=34) indicated that their own personal attitude to menopause was 
positive.  A minority (15.5%, n=11) reported a negative attitude toward menopause.  This proportion 
appeared higher among CAMs users however, where 22.2% reported a negative personal attitude to 
menopause.  However, using a 5% level of significance, a chi-square test provided no significant indication 
that there was a dependency between CAMs usage and attitude to menopausal symptoms (positive, neutral 
or negative) (p-value = 0.27).  
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Table 3: Participants’ personal understanding and attitude toward menopause (n=71) 
 Sample (n=71) CAMs Users (n=27) No CAMs (n=44) 
 Count Proportion Count Proportion Count Proportion 
PERSONAL UNDERSTANDING OF MENOPAUSE 
Natural Life Stage 61 85.9% 27 44.3% 34 55.7% 
Temporary Medical Condition 1 1.4%     1 100.0% 
Permanent Medical Condition 9 1.4%     9 100.0% 
 71 100.0% 27 38.0% 44 62.0% 
       
PERSONAL ATTITUDE TO MENOPAUSE 
Positive Attitude 34 47.9% 11 32.4% 23 67.6% 
Neutral Attitude 26 36.6% 10 38.5% 16 61.5% 
Negative (loss of youth) 2 2.8% 2 100.0%     
Negative (symptoms) 9 12.7% 4 44.4% 5 55.6% 
 71 100.0% 27 38.0% 44 62.0% 
 
The study is aimed at describing CAMs usage in the treatment of menopausal symptoms.  Even though 
women are defined as having experienced menopause once they have not had a menstrual cycle for 12 
months (The North American Menopause Society, 2017b), menopausal symptoms can be experienced within 
the peri-menopausal stage, before actually reaching menopause.  More than 80% (n=58, 81.7%) of the study 
participants reported that their last menstrual cycle was more than 12 months in the past, and thus meet 
the definition for experiencing menopause.  Of the remaining participants, six (8.5%) did not have a 
menstrual cycle in the previous 2-11 months, and seven (9.9%) did have a menstrual cycle within the last 
month. All 13 of these peri-menopausal participants reported symptoms associated with menopause. 
4.3 Severity of menopausal symptoms 
The MRS II was the validated rating scale used to measure and compare the severity of menopausal 
symptoms among participants.  Eleven symptoms were reported across three dimensions, namely somato-
vegetative, psychological and urogenital.  Each symptom had a numeric severity score of 0-4 ranging across 
the five severity levels: None (0), Mild (1), Moderate (2), Severe (3) and Very Severe (4).  The individual 
severity ratings were then aggregated by dimension, and finally an overall MRS II rating was calculated on a 
scale of 0 to 44, with 0 indicating no symptoms and 44 indicating that all 11 symptoms were reported as very 
severe.  The average MRS II ratings are provided in Figure 2 for all participants (11.83), as well as for non- 
CAM/HRT uses, HRT users, CAM users and CAMs + HRT users.  
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Figure 2: Average overall menopausal symptom rating scale scores (0-44) for study participants (n=71) 
 
 
Given that the observed MRS II severity for CAM users (14.19) appeared materially higher than that for the 
entire study (11.83), a t-test was applied to test whether this relationship was statistically significant.  Using 
a 5% level of significance, a t-test indicated that CAM users reported significantly more severe overall 
menopausal symptoms than participants not using CAMs (p-value = 0.02).   
In contrast, the observed MRS II severity for HRT users (11.61) was lower than that for the entire study 
population (11.86), and a t-test was applied to test whether this relationship was statistically significantly.  
Using a 5% level of significance, a t-test provided no significant indication that HRT users reported 
significantly less severe symptom severity than non-HRT users (p-value = 0.40).  Detailed results of statistical 
t-tests are presented in Appendix  4. 
Figure 3 presents the average severity ratings for each MRS II symptom across the entire sample.  The 
individual symptom with the most severe MRS II rating in the sample was sleep problems, which included 
difficulty in falling asleep, difficulty in sleeping through and waking up early.  The average MRS II rating for 
sleep problems across the study was 1.49, compared to the overall average study symptom rating of 1.08, 
and the lowest of 0.69 (bladder problems including difficulty in urinating, increased need to urinate and 
bladder incontinence).    
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Figure 3: Comparative severity of the different menopausal symptoms across the study participants (n=71) 
 
Table 4 provides the average MRS II ratings for each of the eleven symptoms divided into the three 
dimensions.  The averages are provided separately for CAM users and HRT users in addition to the overall 
study result.  Furthermore, averages are provided for participants that used both CAMs and HRT, as well as 
for participants that used neither CAMs nor HRT.  CAMs users experienced more severe symptoms across 
every one of the eleven symptoms compared to all participants.  In line with the overall study result, sleep 
problems were also the most severe symptom across CAM users, non-CAM users, HRT users and non-HRT 
users. 
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Table 4: Average severity of menopausal symptoms and dimensions reported by study participants (n=71) 
Symptom / Dimension Sample CAMs Users HRT Users CAMs+HRT No CAMs/HRT 
  (n=71) (n=27) (n=41) (n=13) (n=16) 
Hot Flushes, Sweating 1.25 1.48 1.27 1.38 0.94 
Heart Discomfort 0.75 0.81 0.73 0.85 0.75 
Sleep Problems 1.49 1.74 1.41 1.54 1.31 
Joint & Muscular Discomfort 1.11 1.30 1.12 1.54 1.13 
Somato-Vegatative (average) 1.15 1.33 1.13 1.33 1.03 
      
Depressive Mood 0.99 1.04 1.07 1.08 0.75 
Irritability 1.13 1.19 1.17 1.15 0.94 
Anxiety 0.96 1.07 1.00 1.08 0.75 
Physical & Mental Exhaustion 1.27 1.59 1.22 1.54 1.06 
Psychological (average) 1.09 1.22 1.12 1.21 0.88 
      
Sexual Problems 1.14 1.41 1.12 1.31 0.88 
Bladder Problems 0.69 1.11 0.56 0.92 0.50 
Dryness of Vagina 1.06 1.44 0.95 1.15 0.75 
Urogenital (average) 0.96 1.32 0.88 1.13 0.71 
      
 
The dimension with the most severe average MRS II rating in the sample was the somato-vegetative 
dimension, which included symptoms such as hot flushes, heart discomfort, sleep problems, joint discomfort 
and muscular discomfort.  The average MRS II rating for somato-vegetative symptoms across the study was 
1.15, compared to 1.09 for the psychological dimension, and 0.96 for the urogenital dimension.   
Similarly, the highest dimension MRS II rating for CAM users was the somato-vegetative dimension, with an 
average dimension MRS II rating for CAM users of 1.33.  The next most severe dimension was only marginally 
less severe, and not significantly so (p-value = 0.95), with an average dimension MRS II rating of 1.32 for the 
urogenital dimension, which included symptoms such as sexual problems, bladder problems and vaginal 
dryness.   
4.4 Complementary and alternative medicines usage 
CAMs were used by 38.0% (n=27) of the participants to treat their menopausal symptoms.  Just over half 
(51.9%) of these CAM users used a single CAM treatment, with the rest using between two and four separate 
treatments, although not necessarily concurrently.  The number of CAM treatments used by each participant 
is summarised in Table 5. 
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Table 5: Number of CAM products used by participants (n=27) 
Number of CAMs Frequency Proportion 
1 14 51.9% 
2 9 33.3% 
3 1 3.7% 
4 3 11.1% 
 27 100.0% 
 
There were five specific CAMs that were used by multiple participants, with calcium, and phyto-oestrogens 
such as soy and Red Clover isoflavones, being the most frequently used, each with 9 participants reporting 
their usage.  Table 6 lists all CAMs where there was reported usage by more than one participant.   
Table 6 combines omega 3 and omega 6 usage into a single category, since three of the eight omega users 
either reported using a combination omega 3 and 6 treatment, or alternatively did not specify the type of 
omega treatment used.  
Table 6: Most frequently used CAMs used by multiple participants (at least 5 reported users) 
Treatment 
Total 
Frequency 
Total 
Proportion 
Phyto-oestrogens 9 33% 
Calcium 9 33% 
Omega (3 and/or 6) 8 30% 
Black Cohosh 6 22% 
Magnesium 5 19% 
 
In addition to the five most frequently used CAMs treatments, there were 14 other vitamins, herbal, 
botanical, amino-acid and homeopathic remedies used, although none were used by more than a single 
participant.  Table 7 lists these CAM treatments together with their active ingredient.  In total, 43.1% of all 
individual CAM treatments were perceived as effective.  
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Table 7: CAMs treatments with limited usage patterns 
Treatment Active Ingredient Type 
Vitamin B Complex B-vitamins Vitamins 
Vital multivitamin for mature women Multiple Vitamins 
Vitamin E E-vitamin Vitamins 
CP Melatonin Melatonin Botanical 
GABA Gamma-aminobutyric acid Amino acid 
SEPIA Sepia Succus, Sepia Officinalis Homeopathic 
KY Jelly  Lubricant 
Kolorex Horopito Herbal 
Solal Hormone Booster 3,4-divanillyltetrahydrofuran Botanical 
Heel ovarium compositum Ovarium suis D8 Homeopathic 
Premular Vitex agnus-castus Herbal 
A Vogel Hot Flush and Night Sweat Remedy  Sage herb Herbal 
Procaps Progesterone compound  Botanical 
Testogel cream Testosterone compound Botanical 
 
While the overall prevalence of CAM usage was 38.0%, this prevalence appeared to be somewhat higher for 
women with more severe symptoms.  Women reporting a MRS II rating of more than 15 were in the 30th 
percentile of most severe symptoms in this study, and at this level CAM usage was 57.9%.   
4.5 Complementary and alternative medicines efficacy 
Participants reported on the efficacy of their CAM interventions across three categories, namely effective, 
partially effective and ineffective.  Participants reported on the effectiveness of individual CAM treatments 
for their menopausal symptoms, with 63.0% (n=17) of CAM users finding at least one CAMs treatment to be 
effective.   
Across the five CAM treatments that were used by more than one participant, only omega (3 and/or 6) and 
magnesium saw more than half of users report the treatment to be effective, with 80% of magnesium users 
reporting effectiveness, and 62.5% of omega users. Black Cohosh had the lowest reported full effectiveness 
levels of 33.3%.  The reported levels of effectiveness are summarised in Figure 4.   
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Figure 4: Efficacy ratings of CAMs users (n=27) for the most commonly used CAMs treatments 
 
Table 8 lists the reported efficacy of CAM products that were used by a single participant.  Of these, only 
three reported the intervention to be effective, namely Vitamin B, Vitamin E and Progesterone compound 
(Procaps).     
Table 8: Efficacy of CAMs treatments with limited usage patterns 
Treatment Active Ingredient Perceived Efficacy 
Vitamin B Complex B-vitamins Effective 
Vital multivitamin for mature women Multiple  
Vitamin E E-vitamin Effective 
CP Melatonin Melatonin Partially Effective 
GABA Gamma-aminobutyric acid Partially Effective 
SEPIA Sepia Succus, Sepia Officinalis Partially Effective 
KY Jelly   
Kolorex Horopito Ineffective 
Solal Hormone Booster 3,4-divanillyltetrahydrofuran Partially Effective 
Heel ovarium compositum Ovarium suis D8 Ineffective 
Premular Vitex agnus-castus Partially Effective 
A Vogel Hot Flush and Night Sweat Remedy  Sage herb Ineffective 
Procaps Progesterone compound  Effective 
Testogel cream Testosterone compound Partially Effective 
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4.6 Comparing complementary and alternative medicine and hormone replacement therapy usage 
There was a significant number of participants who used CAM and HRT treatments concurrently (18.3%), 
although the largest category in this study were HRT users who had not used CAMs (39.4%). Table 9 
summarises the concurrent usage of CAMs and HRT, showing the four possible combinations of CAM users 
and HRT users.  More participants that did not use HRT were non-CAM users (22.5%) rather than CAM users 
(19.7%). 
Table 9: Concurrent CAM and HRT usage patterns of participants (n=71) 
 HRT Users 
Non-HRT 
Users 
Row Totals 
CAM Users 18.3% (n=13) 19.7% (n=14) 38.0% (n=27) 
Non-CAM Users 39.4% (n=28) 22.5% (n=16)  62.0% (n=44) 
Column Totals 57.7% (n=41) 42.3% (n=30) 100.0% (n=71) 
 
Nearly half (48.1%, n=13) of CAM users were also using HRT at the time of the questionnaire, with 51.9% 
(n=14) of CAM users not using HRT to treat their menopausal symptoms.  Altogether, 57.7% (n=41) of the 
participating women reported to be current HRT users, with the rest of participants (42.3%, n=30) not 
currently using HRT.  Of these 30 non-HRT users, 4 participants had previously used HRT but had 
subsequently terminated their usage.  A chi-square test applied to test whether CAM usage was independent 
of HRT usage did not indicate that there was a significant dependence between CAM usage and HRT usage 
(p-value = 0.20). 
Table 10 presents the overall average MRS II score per category, using the same CAM usage vs. HRT usage 
categorisation applied in Table 9.  Participants that were using both CAMs and HRT reported an average MRS 
II rating of 13.5, less than the 14.2 reported by all CAM users.  However, CAM users that were not using HRT 
reported the most severe symptoms with a MRS II rating of 14.8.  Among HRT users, it was found that the 
symptom severity was higher for participants who were also CAM users (13.5) compared to those who did 
not use CAMs (10.8).    
Table 10: Average overall MRS rating for CAMs and HRT users (n=71) 
 HRT No HRT Row Averages 
CAM Users 13.5 14.8 14.2 
Non-CAM Users 10.8 9.8 10.4 
Column Averages 11.6 12.1  
 
4.7 Sources of information for complementary and alternative medicines users 
The 27 participants that used CAMs in the treatment of their menopausal symptoms responded to four 
additional questions around their sources for CAM information and recommendations.  Participants were 
asked to identify all the media sources that they had used to obtain information on CAMs, as well as the key 
individual that they identified as their primary information source.  They were asked to indicate whether 
they had consulted with their medical doctor directly before using CAMs, as well as to identify all the 
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individuals who had provided them with a specific CAM recommendation.  The final question in this section 
of the questionnaire requested the participant’s primary motivation for CAM usage.   
The second section of Table 11 summarises the primary source participants used to obtain information on 
CAMs (“Primary source for CAMs information”), and the questionnaire limited participants to select a single 
choice for this question.  The other three sections in the table report on questions that allowed participants 
to select multiple responses if applicable. 
Table 11: Qualitative assessment by CAM users: information sources, recommendation sources, and 
motivation for CAM usage (n=27) 
SOURCES OF MEDIA UTILISED FOR CAMS 
 Count Proportion 
Internet 16 59.3% 
Magazines 9 33.3% 
Books 5 18.5% 
Other 4 14.8% 
Television 2 7.4% 
   
PRIMARY SOURCE FOR CAMS INFORMATION   
 Count Proportion 
Medical Doctor 9 33.3% 
Internet 8 29.6% 
Pharmacist 4 14.8% 
Friend 2 7.4% 
N/A 2 7.4% 
CAM Practitioner 1 3.7% 
Colleague 1 3.7% 
 27 100.0% 
   
SOURCE OF RECOMMENDATIONS FOR CAMS PRODUCT 
 Count Proportion 
Medical Doctor 17 63.0% 
Friend 5 18.5% 
Pharmacist 4 14.8% 
Family Member 3 11.1% 
Other 3 11.1% 
Colleague 2 7.4% 
CAM Practitioner 1 3.7% 
   
PERSONAL REASONS FOR USING CAMS   
 Count Proportion 
Adverse HRT effects 9 33.3% 
Personal Values 9 33.3% 
Other 9 33.3% 
Lack of efficacy of allopathic medicines 3 11.1% 
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The internet was utilised to obtain information on CAMs by 59.3% of CAM users, although other sources of 
media were also used, including magazines (33.3%), books (18.5%) and television (7.4%).  When asked to 
identify the single main source of information relied on to gather information on CAM treatments, 33.3% of 
CAM users indicated their medical doctor, although this was closely followed by 29.6% who selected the 
internet.  Of the 16 CAM users that used the internet to obtain information on CAMs, 7 of them viewed the 
internet as their single main source of information on the subject, ahead of doctors and other medical 
professionals. 
Nearly two thirds (63.0%) of CAM users consulted with their medical doctor before initiating CAM treatment 
for their menopausal symptoms.  Of these 17 participants, 14 received a recommendation from their medical 
doctor for a specific CAM treatment, and medical doctors were in fact the dominant source for 
recommending specific CAM treatments across all CAM users (63.0%). 
The reasons that participants identified to adopt CAMs as a treatment plan were varied.  Nine participants 
responded that it was due to HRT treatments resulting in adverse side-effects (33.3% of CAM users), and 9 
participants responded that it was due to their personal beliefs or values.  In addition to the three choices 
provided, 9 participants selected the “other” option and specified their own reason for the choice to use 
CAMs, such as: “Needed an energy boost”, “Additional relief of severe symptoms” (2), 
“Recommended/Prescribed” (3), “Family history of breast cancer” (2), and “Environmental concerns”.   
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5. Discussion 
The main purpose of this study was to describe the use of CAMs in the treatment of menopausal symptoms 
by women who access private healthcare in Pretoria, South Africa.  The study also sought to gather 
information on the concurrent usage of CAMs and hormonal treatments, as well as to collect data on the 
sources of information utilised for CAMs. 
5.1 Responses 
Despite opting out of a formal assisted-questionnaire process, several participants did seek clarity from the 
researcher on specific questions while completing the questionnaire - either at the study setting, 
telephonically or by email.  The researcher could resolve all such interactions satisfactorily at a time 
convenient for the participant and was thus able to provide the assistance required.  Of the five comparative 
studies that utilised a questionnaire (Buhling et al., 2014; van der Sluijs et al., 2007; Cardini et al., 2010; 
Gerber et al., 2014; Gollschewki et al., 2004), all except the Gerber et al. (2014) study were designed on a 
self-administration basis, and the preferences indicated by our study validate that self-administration 
appears to be the preferred approach for study participants.  It is however reasonable to believe that the 
four participants who submitted questionnaires that were subsequently excluded may have been identified 
earlier in a guided interview approach. 
5.2 Demographics of participants 
In comparison to the study target age range of 40-65 years, participants’ ages ranged from 44 years to 64 
years with an average age of 54 years.  The average age was in line with the results of Buhling et al. (2014), 
(52.6 years), van der Sluijs et al. (2007), (52.5 years) and Gollschewki et al. (2004) (54.8 years).   
The single-site study was conducted at a private community pharmacy situated in Pretoria.  In aggregate, 
participants indicated a high level of education and a high proportion of salary-earners, which is in line with 
private healthcare patients in South Africa.  While South Africa is not regarded as a developed country, 
consumers of private medical services in South Africa do tend to correspond to a LSM of 8-10 (Hospital 
Association of South Africa, 2008) indicating a higher average living standard compared to the typical South 
African.  As a result, the participants from our study setting would have some level of comparability to results 
of the studies situated in developed countries (Buhling et al., 2014; van der Sluijs et al., 2007; Cardini et al., 
2010; Gollschewki et al., 2004). 
The van der Sluijs et al. (2007), Cardini et al. (2010) and Gerber et al. (2014) studies were conducted out of 
healthcare facilities, which would be broadly comparable the setting for our study, which is a community 
pharmacy and clinic.  It is however not clear from those two studies whether the settings were public or 
private facilities, whereas our study was restricted to a private healthcare facility. 
Cardini et al. (2010) reported no significant differences between demographic groups including age, marital 
status and employment status.  Gerber et al. (2014) did however find that higher levels of education were 
associated with CAM usage.  Our study found no statistically significant dependence between CAM usage 
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and either employment status or educational levels.  Nonetheless, in the post-graduate educational level 
category specifically, there was a lower prevalence of CAM usage observed (25.0%) compared to no usage 
(48.8%), although this pattern was not observed across the other educational level categories. 
5.3 Severity of menopausal symptoms 
Comparing CAM users to the entire sample, they had a higher average MRS score (14.19 vs. 11.83) and higher 
median MRS score (12 vs 11), and as such a statistical test was conducted to test the hypothesis that the 
average MRS score for CAM users is higher than that for non-CAM users.  This test was conducted at a 5% 
level of significance and indicated that CAM usage is associated with more severe menopausal symptoms 
that non-CAM usage.  Furthermore, CAM users experienced more severe symptoms across every one of the 
eleven symptoms compared to the symptoms of non-CAM users.  Although not all the comparative studies 
included an analysis at the symptom level, this finding does align with the van der Sluijs et al. (2007) study 
which found that CAM users considered all menopausal symptoms as more severe compared to non-CAM 
users.        
5.4 Complementary and alternative medicine usage 
The prevalence of CAM usage to treat menopausal symptoms in this study was 38.0%.  Five comparative 
studies found CAM usage ranging from 34% to 83%, with a median study result of 48% (Buhling et al., 2014; 
van der Sluijs et al., 2007; Cardini et al., 2010; Gerber et al., 2014; Gollschewki et al., 2004).  Bosman et al. 
(2008) focused their South African based study on attitudes and beliefs around soy products, rather than 
actual prevalence of usage.   
This study found that calcium and phyto-oestrogens were the most commonly used CAM treatments.  Table 
12 lists the findings from comparative studies with respect to the most common CAMs used. 
Table 12: Most commonly used complementary and alternative medicines in comparative studies 
Study Most commonly used CAMs 
Buhling et al., 2014 St John’s wort (18%), homeopathy (15%) 
Van der Sluijs et al., 2007 Soy (25.4%), omega 6 (18.4%) 
Cardini et al., 2010 Herbal products (41%), soy (26%) 
Gerber et al., 2014 Nutritional remedies (18.8%), herbal remedies (16.9%) 
Gollschewki et al., 2004 Phyto-oestrogens (56%), omega 6 (34%), vitamin E (29%) 
 
Phyto-oestrogens in general are identified by three of these studies as frequently used, in line with the 
finding that 33% of CAM users used phyto-oestrogens in our study.  Gollschewski et al. (2004) found that 
55.8% of participants used phyto-oestrogens, including 10.5 of total participants that used red clover.  The 
Bosman et al. (2008) study focused exclusively on the health benefits of soy and soy products, finding that 
69% of respondents agreed that soy has many health benefits.        
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Table 13 lists some of the known benefits, risks and drug interactions relevant to the five common CAM 
treatments identified in our study.  Due to the differences in risks and benefits, omega 3 and omega 6 have 
been listed separately, although the usage column in Table 13 reflects the combined usage for omega 3 
and/or 6.  
Table 13: Benefits, risks and drug interactions of the CAM treatments most commonly used by study 
participants (n=27) 
CAM 
Treatment 
Usage Possible Benefit Risks Drug Interactions 
Phyto-
oestrogens 
33% Improves hot flushes3 Endometrial 
hyperplasia (Soy 
products)3 
Anticoagulants (Red 
Clover)3 
Black Cohosh 22% Better then placebo for hot flushes3 GI Disturbances3 
Skin rashes10 
Jaundice10 
None known3 
Omega 3 30%* Reduce inflammation of painful joints1 
Lubricate the body thus helping with 
vaginal dryness1 
Reduce the frequency of hot flushes 
with the right dosage1 
GI Disturbances6 Anticoagulants4,6 
Some oral diabetic 
medicines6 
Omega 6 
(EPO) 
30%* Decreases night flushes3 Inflammation3 
Thrombosis3 
Nausea3 
Diarrhoea3 
Anticoagulants2,3 
Phenothiazines2,3 
Calcium 33% Preventing bone loss4 GI Disturbances7 Ceftriaxone7 
Biphosphates7 
Digoxin7 
Gentamycin7 
Magnesium 19% Improves hot flushes9 
Improves insomnia, irritability, agitation 
and anxiety – potential symptoms of 
menopause8 
Nausea and 
vomiting8 
May lower 
blood pressure8 
Possible interaction with 
calcium channel blockers5 
Possible interaction with 
quinolone and tetracycline 
antibiotics as well as 
Nitrofurantoin5 
(1:Menopause Centre Australia, 2016; 2:The North American Menopause Society, 2017a; 3:Sonnedecker, 
2006; 4 :University of Maryland Medical Center, 2015a; 5:University of Maryland Medical Center, 2015b; 
6:University of Maryland Medical Center, 2015c; 7:University of Maryland Medical Center, 2016; 8:University 
of Maryland Medical Center, 2015d; 9:Tonick and Muneyyirci-Delale, 2016; 10:National Center for 
Complementary and Integrative Health, 2017) 
In our study, just less than half of CAM users (48.1%) had used more than a single CAM treatment for their 
menopausal symptoms.  Buhling et al. (2014) found 64.8% of CAM users had used more than one CAM 
intervention, although van der Sluijs et al. (2007) had a far lower finding of 23.7% of CAM users that had 
used two or more products.  
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A few participants (15.4%, n=11) did not use CAMs to treat their menopausal symptoms but did use CAMs 
for the treatment of unrelated conditions.  These participants were excluded from the definition of CAM 
users in our study.  Van der Sluijs et al. (2007) found that nearly a quarter of that study’s participants (25.3%) 
used CAMs for health conditions other than menopause. 
5.5 Complementary and alternative medicines efficacy 
Participants reported on the effectiveness of CAM treatments for their menopausal symptoms, with 63.0% 
(n=17) of CAM users finding at least one CAM treatment effective.  Across the five most commonly used 
treatments, magnesium was reported to be effective by 80% of users, and omega (3 and/or 6) by 62.5% of 
users.  In contrast, van der Sluijs et al. (2007) found that the three most effective CAM treatments were 
phyto-oestrogens, evening primrose oil (EPO) and black cohosh.  Three out of five (60%) of the participants 
in the van der Sluijs et al. (2007) study found at least one practitioner or product to be very effective in 
improving menopausal symptoms, which is almost the same as the 62.5% found in our study. 
None of the eight CAM users that used omega 3 and/or 6 found it ineffective.  In contrast, some studies have 
found that EPO provides no added benefit for menopausal hot flushes or night time sweating (Chenoy et al., 
1994 and van der Westhuizen, 2009) while another agreed that omega 3 has no effect on vasomotor 
frequency or intensity (Cohen, 2009).  Yet, the Menopause Centre of Australia has found that omega 3 can 
decrease the frequency of hot flushes by up to half, with the correct dosage (Menopause Centre Australia, 
2016). 
This study found that phyto-oestrogens were effective in treating symptoms in 44.4% of cases, partially 
effective in 11.1%, and ineffective in 44.4% of the cases.  Soy and Red Clover were CAMs that were classified 
as phyto-oestrogens in this study.  According to the Bosman et al, (2008) study, one third of South African 
women agreed that soy can be used as an alternative to HRT despite only 23% believing that it could relieve 
menopausal symptoms.  Other studies have found phyto-oestrogens the most ineffective CAM treatment 
(Buhling et al., 2014) whereas some evidence of soy improving hot flushes has been reported (Sonnedecker, 
2006), based on a meta-analysis of randomised controlled trials. 
This study found that CAM usage was associated with more severe menopausal symptoms.  Even considering 
only HRT users in isolation, CAM users reported more severe symptoms than non-CAM users.  This may 
indicate that CAMs do not provide high levels of effectiveness when menopausal symptoms are more severe.  
There have been reports that CAM interventions are rated less effective in comparison to HRT where women 
have more severe complaints (Buhling et al., 2014). 
5.6 Comparing complementary and alternative medicines and hormone replacement therapy usage 
There was a meaningful number of participants who used CAMs and HRT concurrently (18.3%).  Van der 
Sluijs et al. (2007) found that 37.4% of respondents were using CAM products in conjunction with some 
pharmaceutical product, and Cardini et al. (2010) found that only 6.8% of respondents used CAMs in 
conjunction with HRT. 
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It is possible that women who experience more severe menopausal symptoms may find that their quality of 
life is significantly impacted and may consequently be more likely to consider a range of interventions, either 
allopathic, complementary, or a combination thereof.  CAM users in our study reported more severe 
symptoms than non-CAM users.  While the study found no dependence between CAM and HRT usage, 
participants that used CAMs alone reported more severe symptoms overall than who used both CAMs and 
HRT.  This is different to a study which reported that menopausal symptoms are significantly higher for users 
of CAMs and HRT together than for CAM users alone (Buhling et al., 2014). 
5.7 Sources of information for complementary and alternative medicines users 
When asked to identify the single main source of information relied on to gather information on CAM 
treatments, 33.3% of CAM users indicated their medical doctor, although this was closely followed by 29.6% 
who selected the internet.  This data aligns with the Cardini et al. (2010) study, which found that medical 
doctors were the most popular source of information (25%), although in contrast the internet was the least 
popular source of information (2%).   
The internet was utilised to obtain some information on CAMs by 59.3% of CAM users in our study.   Of the 
16 CAM users that used the internet to obtain information on CAMs, 7 of them viewed the internet as their 
single main source of information on the subject, ahead of doctors and other medical professionals.  In a 
systemic review of available research, the internet has been identified as the primary source for women 
collecting information regarding CAMs usage for menopausal symptoms (Posadzki, 2013). 
Nearly two thirds (63.0%) of CAM users consulted with their medical doctor before initiating CAM treatment 
for their menopausal symptoms.  Of these 17 participants, 14 received a recommendation from their medical 
doctor for a specific CAM treatment, and medical doctors were in fact the dominant source for 
recommending specific CAM treatments across all CAM users (63.0%).  In contrast to the 63.0% of CAM users 
who received specific CAM recommendations from their medical doctor in our study, only one in five women 
in the van der Sluijs et al. (2007) reference study in Australia had been referred to those treatments by 
medical practitioners. 
Just more than one quarter (27.0%) of CAM users indicated the adverse effects of HRT as the primary 
motivation for CAM usage, in line with the Sonnendecker (2006), findings linking CAM usage with a concern 
for the high risk or adverse effects of conventional treatments.  An additional 11.1% of CAM users selected 
CAMs due to a perceived inefficacy of allopathic medicines in the treatment of their menopausal symptoms. 
5.8 Ethical considerations 
One of the participants reported that she currently used both St John’s Wort and a selective serotonin 
reuptake inhibitor.  The concurrent usage of these two treatments leads to increased risk of developing 
serotonin syndrome, which can be fatal.  The researcher contacted the participant directly to inform her of 
the potential risks associated with this usage pattern and recommended that she seek further advice from 
her medical practitioner. 
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5.9 Study limitations 
The data was collected on a voluntary basis, with potential participants being informed of the study purpose 
before deciding to opt in.  As such, there may have been some selection bias from participants with more 
extreme menopausal symptoms, or a stronger personal support for CAM usage.  This could potentially have 
resulted in either the severity of menopausal symptoms or the prevalence of CAM usage in the study being 
higher than that found the in the general population. 
While the usage of a single-site study setting enables some conclusions to be made with more confidence, 
it also means that it is less appropriate to generalise the study findings to a broader population, such as all 
South African women experiencing menopausal symptoms.  It also makes it more challenging to provide 
meaningful comparisons to other studies in the literature, although significant care has been taken to use 
comparative target demographics, questionnaire and approach to the rating of menopausal symptom 
severity. 
The researcher categorised participants as CAMs users based on her identification of CAM treatments in line 
with the research objectives and prevailing literature.  The study did not consider any complementary 
treatments falling outside of the NCCIH classification of biologically-based systems (U.S. National Library of 
Medicine: National Institutes of Health, 2003).  Furthermore, some CAMs included in this definition, such as 
vitamins, were not identified by all participants as CAMs.  It may have provided useful context for participants 
to include the exact detail of how a CAMs user was defined in the study information sheet.  This definition 
could also have been included in the questionnaire itself in the introduction to Section 4.  
The study did not ask participants to list the exact symptom that each CAM treatment was taken for.  This 
information could potentially have been used to analyse the severity of individual menopausal symptoms in 
the context of the perceived efficacy of the particular CAM taken to treat them. 
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6. Conclusion 
This study described the usage of CAMs within the study setting across several dimensions, namely: 
demographics of study participants, severity of menopausal symptoms, prevalence of CAM usage, and 
individual CAM products used.  Furthermore, the concurrent usage of CAMs and HRT was described, both 
from a prevalence perspective, and from a symptom severity perspective.  Finally, information was gathered 
on the sources of information used by participants on CAM treatments, as well the sources for specific CAM 
recommendations. 
6.1 Summary of findings 
There were 71 women who participated in this single-site study, representing a response rate of 38.1%.  
Participants in the study were predominantly white (93.0%), married (80.3%), income-earning (77.5%) 
women between the ages of 50 and 59 (66.5%).   
The study found that 38.0% of all participants had used CAMs to treat their menopausal symptoms.  More 
than one CAM product was used by 48.1% of CAM users, and in total, 19 different CAM treatments were 
used by the participants to treat their menopausal symptoms.  Of these 19, five CAM treatments were used 
by multiple participants, namely phyto-oestrogens, calcium, omega 3 and/or 6, Black Cohosh and 
magnesium.     
The MRS II scale was used to rank the severity of participants’ menopausal symptoms within the study.  The 
average MRS II rating for all participants was 11.83; in contrast the average MRS II rating for CAM users was 
14.19.  CAM users reported significantly more severe symptoms than non-CAM users (p-value = 0.02).  Sleep 
problems, such as difficulty in falling asleep, difficulty in sleeping through or waking up early were reported 
as the most severe of the eleven measured symptoms across both the entire study and for CAM users.  
Bladder problems were reported as the least severe symptoms across all participants, although heart 
discomfort was reported as the least severe symptom by CAM users.   
Around 63.0% of CAM users found at least one of the CAM treatments that they used to be effective, with 
43.1% of all individual CAM treatments being perceived as effective.  Magnesium was perceived to be the 
most effective in treating menopausal symptoms of the five common CAM treatments, with 80% of users 
reporting it effective, and 20% reporting it partially effective.  Black Cohosh was perceived to be the least 
effective of the five, with half its users perceiving it to be ineffective.   
There was a meaningful proportion of participants (18.3%) who used both CAM and HRT treatments 
concurrently.  HRT users reported less severe symptoms than CAM users (MRS II rating 11.6 vs. 14.2), 
although whether this is due to HRT treatments being more effective than CAM treatments, or whether 
women who display more severe symptoms are more likely to use CAMs, is unclear. 
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Seventeen CAM users (63.0%) consulted with their medical doctor in some way before initiating CAM 
treatment for their menopausal symptoms.  Of these 17 participants, 14 received a recommendation from 
their medical doctor for a specific CAM treatment, and medical doctors were in fact the dominant source for 
recommending specific CAM treatments across all CAM users (63.0%).  Nonetheless, the single primary 
source used by participants to gather information on CAMs was the internet, with 59.3% of CAM users using 
the online resource as their primary information source.   
6.2 Recommendations 
Recommendations have been made to address challenges that have arisen from this study, or to highlight 
secondary questions that have developed from the study findings.  These recommendations and questions 
are intended to contribute to the shaping of future research into the usage of CAMs for the treatment of 
menopausal symptoms. 
This study has found that CAM usage is associated with significantly more severe menopausal symptoms 
than non-CAM usage.  Future research should identify any qualitative reasons behind this relationship, and 
whether the association is causal in nature.  It may be the case that women with the most severe menopausal 
symptoms are more motivated to actively seek a wider range of treatment interventions beyond the 
traditional HRT approach, in an attempt to counteract their decreased quality of life. 
Future research should also consider using the MRS II scale to maximise comparability of results around 
symptom severity.  More work can be done to standardise the definitions of CAM, and in particular to 
consider comparative analysis of traditional, complementary and alternative practitioners and medicines.  
Individual CAMs could be analysed in the context of the specific symptom that they are intended to treat.  
Research comparing the popularity of individual CAMs to their efficacy may also be illuminating. 
The study has focused on participants who have experienced menopausal symptoms.  Future research 
should investigate whether CAMs usage is related to stages of menopause, and in particular whether CAMs 
usage patterns vary between the peri-menopausal phase and post-menopausal phase.  This could be 
achieved by tracking individual participants throughout their menopause. 
Finally, there is room to perform an investigation into the potential and actual occurrences of drug-herb 
interactions.  This could potentially be aligned with the work of the National Adverse Drug Event Monitoring 
Centre under the South African government Department of Health (Medicines Control Council, 2017).  
Where there are known risks, such as the concurrent use of St John’s Wort and Selective Serotonin Reuptake 
Inhibitor’s, these could be the subject of specific research. 
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8. Appendix 1: Questionnaire 
 
 
 
 
Mrs Lynn Randall        Tel: 083 380 2340 
Dr Mea van Huyssteen      Tel: 0219592864 
School of Pharmacy, University of the Western 
Cape, Robert Sobukwe Road, Bellville, Cape 
Town, 7535 
The use of complementary and alternative medicines in the treatment of menopausal symptoms by private 
health-care patients in Pretoria, South Africa 
UNIQUE IDENTIFIER (OFFICIAL USE ONLY): ______________ 
SECTION 1: DEMOGRAPHIC INFORMATION 
1. Current Age: 
 
 
2. Race: *OPTIONAL* 
Asian Black Coloured Indian White 
 
Other (please specify):  _______________________________________________________________ 
3. Marital Status: 
Single Married Divorced Widowed 
 
4. Highest Level of Education 
Some High 
School 
Matric Diploma Degree Post Graduate 
 
5. Employment Status 
Employed Full 
time 
Employed Part 
Time 
Self-Employed Unemployed Retired 
 
http://etd.uwc.ac.za/
53 | P a g e  
 
SECTION 2: PHILOSOPHY TOWARD MENOUPAUSAL STATUS 
6. Tick the one box that most closely represents your personal understanding of menopause in your 
life 
Natural Life Stage   
Temporary medical condition  
Permanent chronic medical condition  
 
7. Tick the one box that most closely represents your personal attitude toward menopause 
Positive Attitude  
Neutral Attitude  
Negative due to loss of youth  
Negative due to loss of fertility  
Negative due to menopausal symptoms  
 
SECTION 3: MENOPAUSAL SYMPTOMS AND TREATMENT 
8. When did your menopause start? (when was your last menstrual cycle)? 
More than 12 months ago  
2 – 11 months ago  
One month or less ago  
 
9. Did the onset of your menopause coincide with a bilateral oophorectomy or damage to the ovaries 
caused by pelvic radiation, chemotherapy or other medicines? 
Yes No 
 
10. Are you currently using Hormone Replacement Therapy (HRT)? 
Yes No 
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11. Complete the Menopause Rating Scale (MRS) (Berlin Centre for Epidemiology and Health Research, 
2008) 
For each listed symptom, tick the severity of the symptoms that you have experienced within the 
last 4 months.  Tick ‘none’ for symptoms that do not apply to you. 
 
Symptom 
 
N 
o 
n 
e 
 
M 
i 
l 
d 
 
M 
o 
d 
e 
r 
a 
t 
e 
 
S 
e 
v 
e 
r 
e 
 
Very 
Severe 
            
1 Hot flushes, sweating           
            
2 Heart discomfort (unusual awareness of 
heartbeat, heart skipping, heart racing, tightness) 
          
            
3 Sleep problems (difficulty in falling asleep, 
difficulty in sleeping through, waking up early) 
          
            
11 Joint and muscular discomfort (pain in 
the joints, rheumatoid complaints) 
          
            
4 Depressive mood (feeling down, sad, on the 
verge of tears, lack of drive, mood swings) 
          
            
5 Irritability (feeling nervous, inner tension, 
feeling aggressive) 
          
            
6 Anxiety (inner restlessness, feeling panicky)           
            
7 Physical and mental exhaustion 
(general decrease in performance, impaired memory, 
decrease in concentration, forgetfulness) 
          
            
8 Sexual problems (change in sexual desire, in 
sexual activity and satisfaction) 
          
            
9 Bladder problems (difficulty in urinating, 
increased need to urinate, bladder incontinence) 
          
            
10 Dryness of vagina (sensation of dryness or 
burning in the vagina, difficulty with sexual 
intercourse) 
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12. Please list any medicines that you are currently taking, or have previously taken since the onset of your menopausal symptoms.  Please include all 
medicines (allopathic and OTC), complementary and alternative medicines (CAMs) and supplements, both prescribed and self-medicated. This is 
not restricted to medicines taken for the treatment of menopause. 
 
Medicine / CAM Dosage Frequency Date Started Date Stopped Reason for stopping Effectiveness 
(Circle One) 
Name of medicine, CAM or supplement Quantity of 
medicine consumed 
at each dosage 
Number of doses 
taken per day 
Date that you 
started taking the 
medicine 
Date that you 
ceased to take the 
medicine 
Reason that you ceased to take the 
medicine, if applicable (adverse 
effects etc.) 
Effective, 
Ineffective or 
Partially 
Effective 
      E  /  I  /  P 
      E  /  I  /  P 
      E  /  I  /  P 
      E  /  I  /  P 
      E  /  I  /  P 
      E  /  I  /  P 
      E  /  I  /  P 
      E  /  I  /  P 
      E  /  I  /  P 
      E  /  I  /  P 
      E  /  I  /  P 
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SECTION 4: COMPLEMENTARY AND ALTERNATIVE MEDICINES 
Complete this section only if you entered complementary or alternative medicines (CAMs) in 
Question 12 
13. Did you consult with your healthcare practitioner before using CAMS treatment for 
menopause? 
No  
Yes  
 
14. Did any of the following recommend a specific CAM treatment?   
Tick all that apply. 
Family 
Member 
Friend Colleague 
Medical 
Doctor 
CAM 
Practitioner 
Pharmacist 
 
Other (please specify): ____________________________________________________________ 
 
15. Which sources of information you have referred to regarding your CAM usage?  
Tick all that apply. 
TV Internet Books Magazines 
  
Other (please specify): _________________________________________________________ 
 
16. What is the single main source of information that you have referred to regarding 
your CAM usage?  
Family 
Member 
Friend Colleague 
Medical 
Doctor 
CAM 
Practitioner 
TV Internet Books Magazines Pharmacist 
  
Other (please specify): ________________________________________________________ 
 
17. Why did you decide to try CAMS as a treatment for your menopausal symptoms? 
Tick all that apply. 
Personal beliefs/ values  
Adverse effects on allopathic (regular) HRT  
Efficacy of allopathic meds  
Other (please specify)  
 
Thank you for taking the time to participate in my study. Your answers and feedback 
are valuable to me. 
http://etd.uwc.ac.za/
57 | P a g e  
 
9. Appendix 2: Study information sheet 
 
 
 
 
Mrs Lynn Randall        Tel: 083 380 2340 
Dr Mea van Huyssteen      Tel: 0219592864 
School of Pharmacy, University of the Western 
Cape, Robert Sobukwe Road, Bellville, Cape 
Town, 7535 
The use of complementary and alternative medicines in the treatment of menopausal 
symptoms by private health-care patients in Pretoria, South Africa 
STUDY INFORMATION SHEET 
INTRODUCTION: 
You are being invited to take part in a clinical research study conducted by Mrs Lynn Randall, 
a master’s student from the School of Pharmacy at the University of the Western Cape.  The 
study is being carried out at The Medicine Shop Pharmacy in Groenkloof, Pretoria, where I 
work as a Pharmacist. The study is entitled: The use of complementary and alternative 
medicines in the treatment of menopausal symptoms in private healthcare patients in 
Pretoria, South Africa. 
Before you decide whether you wish to take part in this study, you should read the provided 
information sheet carefully. If you wish to discuss it with your family, friends or GP, then 
please take the time to do so. Take time to ask questions – do not feel rushed or under any 
obligation to make a hasty decision.  
You are not obliged to take part in this study and failure to participate will have no effect on 
your future care. You may change your mind at any time (before the start of the study or even 
after you have commenced the study) for whatever reason without having to justify your 
decision and without any negative impact on the care you will receive from the pharmacy. 
WHY IS THIS STUDY BEING DONE?  
The purpose of my research study is to gather information about the prevalence of 
Complementary and Alternative Medicines (CAMs) usage for the treatment of menopausal 
symptoms by women in Pretoria.  Many studies regarding the use of CAMS in menopause 
have been done in various parts of the world, but none as yet in South Africa. This study will 
http://etd.uwc.ac.za/
58 | P a g e  
 
help determine whether the use of CAMS in menopausal women in South Africa is consistent 
with the worldwide trend of CAMS usage in the treatment of menopausal symptoms.  I also 
intend to gather information on the simultaneous usage of CAMs with Hormone Replacement 
Therapy (HRT), allopathic medicines and complementary treatments, as well as the sources 
that people use to obtain information regarding CAMs usage. 
PROCEDURE 
If you agree to be a participant I will contact you to set up a convenient time for the interview. 
The interview/ guided questionnaire will take place at The Medicine Shop Pharmacy in 
Pretoria at should last no more than 20 minutes. We will work through a 17-question 
questionnaire, ensure that you understand the detail behind each question, and document 
your answers.  Alternatively, should you be fluent in English you may also choose to complete 
the questionnaire electronically.   The questionnaire will be emailed to you in a Word format 
and you may either complete it electronically, or else complete a paper copy and then scan 
the completed questionnaire.  Once you have completed the questionnaire, you should email 
it back to the researcher by replying to the original email address.  After receiving and printing 
your completed questionnaire, the researcher will delete the email in order to protect your 
personal information.        
RISKS AND BENEFITS 
This study raises no concern about participant safety or medical welfare, with no risks 
associated with participating in this study.  There are no anticipated direct benefits to you as 
a participant.  All participants enrolled in the study participate on a voluntary basis. 
CONFIDENTIALITY AND ANONIMITY  
All information provided by you during the study will be kept confidential.  No personal or 
identifying information will be included in my final research, with all results presented in a 
combined form.  On completion of the study, the sample data will be kept for a period of two 
years after which it will be destroyed by paper shredding.  
VOLUNTARY PARTICIPATION 
Participation in this study is the sole decision of the participant and your participation is 
completely voluntary. If you agree to partake in the study, you will need to sign a consent 
form before your information may be collected. You may withdraw from the study at any 
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time. Withdrawal from the study will not affect the participants’ relationship with the 
pharmacy in any way. 
            IF YOU REQUIRE FURTHER INFORMATION 
Any further queries or information required may be directed to: 
Lynn Randall 
MOBILE: +27 833802340 
EMAIL: lynn@therandalls.co.za 
OR 
Dr Mea van Huyssteen  
Pharmacy building, First floor Room F6, School of Pharmacy, University of the Western Cape, 
Robert Sobukwe Road, Bellville, 7535, South Africa. 
Tel:  +2721 9592864 
The committee giving ethical approval for this study is the UWC Biomedical Research Ethics 
Committee. The biomedical research ethics administration is available in the Research Office 
in the New Arts Building, C-Block, Top Floor, Room 28 at the University of the Western Cape, 
Robert Sobukwe Road, Bellville, South Africa. If you have any problems or questions about 
this study you can also contact the Ethics committee directly at telephone number 021 
9593170. 
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10. Appendix 3: Informed consent 
 
 
 
 
Mrs Lynn Randall               Tel: 083 380 2340 
Dr Mea van Huyssteen      Tel: 0219592864 
School of Pharmacy, University of the Western 
Cape, Robert Sobukwe Road, Bellville, Cape Town, 
7535 
STUDY TITLE: The use of complementary and alternative medicines in the treatment of 
menopausal symptoms in private healthcare patients in Pretoria, South Africa. 
UNIQUE ID (Official Use Only): ___________ 
I confirm that I have read and understood the study information sheet, and that I have had ample 
opportunity to ask questions all of which have been satisfactorily answered.   Yes   No 
 
I understand that my participation in this study is entirely voluntary and that I may withdraw at 
any time, without giving reason, and without this decision affecting my future treatment or medical 
care.        Yes     No 
 
I understand that my identity will remain confidential at all times and that all the information that 
I provide will be kept at a secure location and will be destroyed after 2 years of the report being 
written.  Yes   No 
 
I have been given a copy of the Patient Information Leaflet and this Consent form for my records. 
  Yes  No 
 
_____________________________ ____________________________ 
Signature and date: Name in block capitals: 
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To be completed by the Person Taking the Consent 
 
I, the undersigned, have taken the time to fully explained to the above patient the nature and purpose 
of this study in a manner that he/she could understand. I have explained the risks involved, the 
experimental nature of the treatment, as well as the possible benefits and have invited him/her to 
ask questions on any aspect of the study that concerned them. 
 
 
___________________ ______________________________ ____________________ _______ 
Signature: Name in Block Capitals: Qualification: Date: 
 
2 copies to be made: 1 for patient and 1 for researcher records. 
 
The committee giving ethical approval for this study is the UWC Biomedical Research Ethics 
Committee. The biomedical research ethics administration is available in the Research Office 
in the New Arts Building, C-Block, Top Floor, Room 28 at the University of the Western Cape, 
Robert Sobukwe Road, Bellville, South Africa. If you have any problems or questions about 
this study you can also contact the Ethics committee directly at telephone number 021 
9593170. 
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11. Appendix 4: Results of statistical tests 
11.1 Comparison of MRS II scores for CAMs users vs. non-CAMs users 
H0: There is no difference in the variance of MRS scores between CAMs users and non-CAMs 
users     
Table 14: F-Test Two-Sample for Variances 
 
No CAMs CAMs 
Mean 10.38636364 14.18518519 
Variance 55.73097252 41.6951567 
Observations 44 27 
df 43 26 
F 1.336629406 
 
P(F<=f) one-tail 0.217738516 
 
F Critical one-tail 1.842924793 
 
 
The F test statistic (1.34) is less than the test critical value at 5% level of significance (1.753) 
and it can therefore not be said that there is a significant difference between the variances of 
the two groups.  Assuming equal variances of MRS score, a t-test is then applied to test 
whether there is a significant difference in MRS scores between CAMs users and non-CAMs 
users. 
 H0: There is no difference in the average MRS scores between CAMs users and non-CAMs users  
Table 15: t-Test Two-Sample assuming equal Variances 
 
No CAMs CAMs 
Mean 10.38636364 14.18518519 
Variance 55.73097252 41.6951567 
Observations 44 27 
Pooled Variance 50.44211438 
 
Hypothesized Mean Difference 0 
 
df 69 
 
t Stat -2.187919291 
 
P(T<=t) one-tail 0.016032565 
 
t Critical one-tail 1.667238549 
 
P(T<=t) two-tail 0.03206513 
 
t Critical two-tail 1.994945415 
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The t test statistic (-2.18) is less than the test critical value at 5% level of significance (-1.667) 
and the null hypothesis is therefore rejected.  CAMs usage is therefore associated with 
significantly more severe menopausal symptoms than non-CAMs usage.   
11.2 Comparison of MRS II scores for HRT users vs. non-HRT users 
A similar approach was followed to determine whether HRT usage is associated with more 
severe menopausal symptoms.  In this test, it was seen that the variance of MRS scores 
between HRT users and non-users was not significant (p-value = 0.34).  Furthermore, the 
application of a t-test could not reject the hypothesis that mean MRS scores for HRT users 
(11.6) and HRT non-users (12.1) are the same (p-value = 0.40).  HRT usage could not be 
significantly associated with less severe menopausal symptoms. 
Table 16: t-Test Two-Sample assuming equal Variances 
    
HRT No HRT 
Mean 11.63414634 12.1 
Variance 57.98780488 48.23103448 
Observations 41 30 
Pooled Variance 53.88713326 
 
Hypothesized Mean 
Difference 
0 
 
df 69 
 
t Stat -0.264137676 
 
P(T<=t) one-tail 0.396230583 
 
t Critical one-tail 1.667238549 
 
P(T<=t) two-tail 0.792461165 
 
t Critical two-tail 1.994945415 
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